

General information about company	
Name of The Company	ANG Lifesciences India Limited
BSE Scrip Code	540694
NSE Symbol	
MSE Symbol	
Date of Start of Financial Year	01-04-2021
Date of End of Financial Year	31-3-2022
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2021
Date of End of Reporting Period	31-03-2022
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions																							
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty				Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Opening balance						Closing balance	Nature of indebtedness (loan/ advance/ inter-corporate deposit/ investment etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilized (specify the nature of the transaction)		
1	ANG Lifesciences India Limited	AAHCA5390H	Rajesh Gupta	AAQPG4797C	Promoter & Managing Director				A approved by Audit committee	54	-6.27	-0.22											
2	ANG Lifesciences India Limited	AAHCA5390H	Rajesh Gupta	AAQPG4797C	Promoter & Managing Director	Any other transaction	Rent Paid		A approved by Audit committee	3	-1.39	-0.3											
3	ANG Lifesciences India Limited	AAHCA5390H	Rajesh Gupta	AAQPG4797C	Promoter & Managing Director	Loan			A approved by Audit committee	97	0	0											
4	ANG Lifesciences India Limited	AAHCA5390H	Rajesh Gupta	AAQPG4797C	Promoter & Managing Director	Any other transaction	loan repaid		A approved by Audit committee	97	0	0											
5	ANG Lifesciences India Limited	AAHCA5390H	Saruchi Gupta	ALAPG5353R	Promoter & Wholetime Director	Remuneration			A approved by Audit committee	24.75	-0.91	-0.71											
6	ANG Lifesciences India Limited	AAHCA5390H	Sudesh Kumari	ADMPK1857E	Non-Executive Non-Independent Director	Any other transaction	Sitting Fee		As Approved by NRC	0.4	0	0											
7	ANG Lifesciences India Limited	AAHCA5390H	Pawanjit Singh	ACUPS4040C	Non-Executive Independent Director	Any other transaction	Sitting fees		As Approved by NRC	0.45	0	0											
8	ANG Lifesciences India Limited	AAHCA5390H	Sulhpal Singh	ABMPS4053N	Non-Executive Independent Director	Any other transaction	Sitting Fee		As Approved by NRC	0.35	0	0											
9	ANG Lifesciences India Limited	AAHCA5390H	Chetna	AVEPC8499A	Non-Executive Independent Director	Any other transaction	Sitting Fee		As Approved by NRC	0.35	0	0											
10	ANG Lifesciences India Limited	AAHCA5390H	Remu Kaur	CJIPK0609N	KMP- Company Secretary	Remuneration			As Approved by NRC	2.1	-0.26	-0.36											
11	ANG Lifesciences India Limited	AAHCA5390H	Subodh Sharma	ADNPS9468G	KMP- Chief Financial Officer	Remuneration			As Approved by NRC	15	-13.22	-12.91											
12	ANG Lifesciences India Limited	AAHCA5390H	Renatus Meditech Solutions Pvt. Ltd	AAKCR1772R	Company's Promoter Mr. Rajesh Gupta holds shareholding	Advance			As Approved by Board	11.32	48	100					Advance	0	NA	Unsecured	bu pu		
13	ANG Lifesciences India Limited	AAHCA5390H	Renatus Meditech Solutions Pvt. Ltd	AAKCR1772R	Company's Promoter Mr. Rajesh Gupta holds shareholding	Any other transaction	Advance taken back		As Approved by Board	61.22	0	0					Advance	0	NA	Unsecured	Ad take		
14	ANG Lifesciences India Limited	AAHCA5390H	Renatus Meditech Solutions Pvt. Ltd	AAKCR1772R	Company's Promoter Mr. Rajesh Gupta holds shareholding	Purchase of goods or services			As Approved by Board	2.39	0	-2.39											
15	ANG Lifesciences India Limited	AAHCA5390H	Baddi agro Pvt. Ltd	AAJCB7928E	Company's Promoter Significant Influence	Advance			As Approved by Board	1453	0	1438					Advance	0	NA	Unsecured	bu pu		
16	ANG Lifesciences India Limited	AAHCA5390H	Baddi agro Pvt. Ltd	AAJCB7928E	Company's Promoter Significant Influence	Any other transaction	Advance taken back		As Approved by Board	15	0	0					Advance	0	NA	Unsecured	Ad take		
17	ANG Lifesciences India Limited	AAHCA5390H	Mansa Print & Publishers Ltd	AADCM9521E	Wholly Owned Subsidiary	Sale of goods or services			As Approved by Board	17.19	0	0											
18	ANG Lifesciences India Limited	AAHCA5390H	Mansa Print & Publishers Ltd	AADCM9521E	Wholly Owned Subsidiary	Purchase of goods or services			As Approved by Board	895.72	-366.02	-318.23											
19	ANG Lifesciences India Limited	AAHCA5390H	Mansa Print & Publishers Ltd	AADCM9521E	Wholly Owned Subsidiary	Any other transaction	Loan repaid		As Approved by Board	301.69	-301.69	0					Loan	0	NA	Unsecured	bu pu		
20	ANG Lifesciences India Limited	AAHCA5390H	Mansa Print & Publishers Ltd	AADCM9521E	Wholly Owned Subsidiary	Any other transaction	Commission Income		As Approved by Board	8.04	6.08	14.13											
Total value of transaction during the reporting period											3059.97												

Text Block	
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	
Textual Information(5)	
Textual Information(6)	
Textual Information(7)	
Textual Information(8)	
Textual Information(9)	
Textual Information(10)	
Textual Information(11)	
Textual Information(12)	
Textual Information(13)	Advance taken back
Textual Information(14)	Notes: 1. The value of the Related Party transactions denotes the amount approved by Audit committee/ Board of Directors. 2. As approved by Board of Directors and shareholders of the Company. 3. As per guideline note for disclosure of related party transaction dated 25th april, 2022, issued by the Stock Exchange, since the company is filling the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure. 4. KMP- Key Managerial Personnel. 5. NRC- Nomination & Remuneration Committee.
Textual Information(15)	Notes: 1. The value of the Related Party transactions denotes the amount approved by Audit committee/ Board of Directors. 2. As approved by Board of Directors and shareholders of the Company. 3. As per guideline note for disclosure of related party transaction dated 25th april, 2022, issued by the Stock Exchange, since the company is filling the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure. 4. KMP- Key Managerial Personnel. 5. NRC- Nomination & Remuneration Committee.
Textual Information(16)	Notes: 1. The value of the Related Party transactions denotes the amount approved by Audit committee/ Board of Directors. 2. As approved by Board of Directors and shareholders of the Company. 3. As per guideline note for disclosure of related party transaction dated 25th april, 2022, issued by the Stock Exchange, since the company is filling the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure. 4. KMP- Key Managerial Personnel. 5. NRC- Nomination & Remuneration Committee.
Textual Information(17)	Notes: 1. The value of the Related Party transactions denotes the amount approved by Audit committee/ Board of Directors. 2. As approved by Board of Directors and shareholders of the Company. 3. As per guideline note for disclosure of related party transaction dated 25th april, 2022, issued by the Stock Exchange, since the company is filling the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure. 4. KMP- Key Managerial Personnel. 5. NRC- Nomination & Remuneration Committee.
Textual Information(18)	Notes: 1. The value of the Related Party transactions denotes the amount approved by Audit committee/ Board of Directors. 2. As approved by Board of Directors and shareholders of the Company. 3. As per guideline note for disclosure of related party transaction dated 25th april, 2022, issued by the Stock Exchange, since the company is filling the RPT disclosure in PDF format, the PAN details are not to be included in the disclosure. 4. KMP- Key Managerial Personnel. 5. NRC- Nomination & Remuneration Committee.
Textual Information(19)	
Textual Information(20)	